Claire Mazumdar Named Future Successor to Kiran Mazumdar-Shaw at Biocon
NEW DELHI — Claire Mazumdar, a U.S.-based biotechnology entrepreneur and chief executive of a Nasdaq-listed company, has been identified as the future successor to Biocon founder and Chairperson Kiran Mazumdar-Shaw.
Mazumdar-Shaw said Tuesday that she has formally mapped out a succession plan for Biocon and chosen her niece, Claire Mazumdar, to eventually take over leadership of the company.
She said that, as Biocon’s sole owner, it was important to ensure the business is placed in capable hands. She added that Claire has shown the ability to lead and manage a company effectively.
However, Mazumdar-Shaw said the transition will not happen immediately. In a social media post, she said she does not plan to step down anytime soon and that Claire will gradually move into the leadership role over time.
Claire Mazumdar, 37, is the founding CEO of Bicara Therapeutics, a Boston-based clinical-stage biotechnology company focused on developing cancer therapies. Under her leadership, the company has grown significantly, with its market capitalization crossing $1.6 billion.
She has a strong scientific and business background, with a degree in biological engineering from the Massachusetts Institute of Technology, an MBA from Stanford Graduate School of Business and a Ph.D. in cancer biology from Stanford School of Medicine.
Before becoming CEO of Bicara in 2020, Mazumdar worked at Third Rock Ventures and led business development and corporate strategy at Rheos Medicines.
She is also a board member of Noora Health, a nonprofit organization focused on improving health care outcomes through patient and caregiver education.
Mazumdar-Shaw said Claire will be supported by a broader family-led leadership structure that includes her brother, Eric Mazumdar, an artificial intelligence expert and professor at the California Institute of Technology, and her husband, Thomas Roberts, an oncologist at Massachusetts General Hospital. (Source: IANS)
